Daiichi Sankyo Company, Limited (4568.T)

5.289,00 -35,00 (-0,66%) Börsenschluss: 03:15PM JST

Daiichi Sankyo Company, Limited

3-5-1, Nihonbashi-honcho
Chuo-ku
Tokyo 103-8426
Japan
81 3 6225 1111
https://www.daiichisankyo.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Sunao Manabe D.V.M., Ph.D.	Group CEO & Executive Chairperson	280M	N/A	1954
Mr. Hiroyuki Okuzawa	President, COO & Representative Director	110M	N/A	1962
Kentaro Asakura	Vice President of Corporate Communications Department	N/A	N/A	N/A
Ms. Marielle Cohard-Radice M.D.	Global Head of Development	N/A	N/A	N/A
Akio Sakurai	Corporate Officer, Head of Sales and Marketing Div. & Japan Business Unit	N/A	N/A	N/A
Takashi Matsumoto	Managing Executive Officer, Head of Global HR & CHRO	N/A	N/A	N/A
Mr. Joji Nakayama	Senior Adviser	154M	N/A	1950
Mr. Kiminori Nagao	Corporate Officer & Head of ASCA Business Division	N/A	N/A	N/A
Mr. Joseph Kenneth Keller	Head of Oncology Business Unit	N/A	N/A	1963
Mr. Stuart Mackey J.D.	Global Head of Business Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in JPY.

Beschreibung

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Corporate Governance

Daiichi Sankyo Company, Limiteds ISS Governance QualityScore, Stand 1. Mai 2024, lautet 1. Die grundlegenden Scores sind Audit: 1, Vorstand: 1, Shareholderrechte: 2, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.